Promoter holding
64.27%
CP
Crms Pharmaceutical Private Limited - Due diligence report
A 360° intelligence report on Crms Pharmaceutical Private Limited: trust score, financial health, credit view, compliance, directors, growth…
CP
Crms Pharmaceutical Private Limited
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Crms Pharmaceutical Private Limited — 360° Intelligence Report
Generated from MCA filings & public records71/100
Trust Score
Moderate
Crms Pharmaceutical Private Limited is assessed as Moderate with a Trust Score of 71/100. Crms Pharmaceutical Private Limited is an active private limited indian non-government company incorporated in 2017, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.
Report generated on 10 Jul 2026 from the latest processed filings. Crms Pharmaceutical Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
71/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
25/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 2 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- No open charges - unencumbered balance sheet.
Charges position: 0 open (-) · 0 satisfied (-).
Compliance Score: 100/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- 1 active GST registration(s).
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RITESH MADAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHEFALI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJ KUMARI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
06
Ownership & Group Intelligence
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 60
Growth signals & trust indicators
Revenue acceleration: +1.42 over 1 year(s).
Latest year revenue grew 2.1x.
Asset base grew 24% - capacity expansion.
Operating for 8 years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
Negative net worth.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment53/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
Investor view60/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 7 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
02 Dec 2023
Director ceased
SUBHASH CHAND MADAN
04 Dec 2017
Incorporated
Registered with Roc Haryana
Director appointed
RITESH MADAN (Director)
Director appointed
SHEFALI (Director)
Director appointed
RAJ KUMARI (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 1 financial year(s).
Net profit margin moved from 38% to 1.42.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
| Company | CIN | Location |
|---|---|---|
| Srph Lifescience | U51909GJ2016PTC094155 | Ahmedabad, Gujarat, India |
| Maxima Herbal Care Private Limited | U74999UR2017PTC007977 | Haridwar, Uttarakhand, India |
| Novell Pharma Private Limited | U24230TG2015PTC098025 | Hyderabad, Telangana, India |
| Akira Pharma Private Limited | U51101DL2009PTC196057 | New Delhi, Delhi, India |
| Safex Pharmaceuticals Private Limited | U74999BR2013PTC020242 | Patna, Bihar, India |
| Deshbhakt Pharmaceutical Private Limited | U74999MH2018PTC315303 | Nagpur, Maharashtra, India |
| Remab Pharmaceuticals Private Limited | U24100WB2013PTC190819 | Kolkata, West Bengal, India |
| Atreo Pharmaceuticals Private Limited | U33119PN2019PTC182490 | Kolhapur, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Crms Pharmaceutical Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Crms Pharmaceutical Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 85/100, margin trends, ownership structure and peer set for Crms Pharmaceutical Private Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 71/100, distress signals and MSME payment-delay disclosures - know whether Crms Pharmaceutical Private Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Crms Pharmaceutical Private Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Crms Pharmaceutical Private Limited an active company?
Crms Pharmaceutical Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).
Is Crms Pharmaceutical Private Limited financially healthy?
Crms Pharmaceutical Private Limited has a Financial Health Score of 25/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Crms Pharmaceutical Private Limited?
Its overall Trust Score is 71/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Crms Pharmaceutical Private Limited?
See the directors and ownership sections above for board and shareholding detail. 3 active director(s) are on record.
Does Crms Pharmaceutical Private Limited have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Crms Pharmaceutical Private Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).
Is it risky to lend to Crms Pharmaceutical Private Limited?
Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
